Keros Therapeutics Inc
KROS14.620USD
+0.300+2.09%
收盤 08/04, 16:00（美東）報價延遲15分鐘
593.02M總市值
140.79本益比TTM
關於 Keros Therapeutics Inc 公司
Keros Therapeutics, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於開發和商業化新型療法，以治療一系列與轉化生長因子-β (TGF-B) 蛋白家族信號傳導功能障礙相關的疾病患者。該公司的主要候選產品 KER-050 正在開發中，用於治療骨髓增生異常綜合徵患者和骨髓纖維化患者的低血細胞計數或血細胞減少症（包括貧血和血小板減少症）。該公司的第二個候選產品 KER-012 正在開發中，用於治療肺動脈高壓 (PAH) 和心血管疾病。該公司的第三個候選產品 KER-065 正在開發中，用於治療肥胖症和神經肌肉疾病。KER-050 旨在通過抑制 TGF-B 蛋白家族子集的信號傳導來促進造血，從而增加紅細胞和血小板的生成。
公司簡介
公司代碼KROS
公司名稱Keros Therapeutics Inc
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
員工數量169
證券類型Ordinary Share
年結日Apr 08
公司地址1050 Waltham Street, Suite 302
城市LEXINGTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02421
電話16173146297
網址https://www.kerostx.com/
公司代碼KROS
上市日期Apr 08, 2020
CEODr. Jasbir Seehra, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Justin Frantz
Mr. Justin Frantz
Head of Investor Relations
Head of Investor Relations
--
--
Mr. Keith C. Regnante
Mr. Keith C. Regnante
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Mr. Christopher R. Rovaldi
Mr. Christopher R. Rovaldi
President, Chief Operating Officer
President, Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Jasbir Seehra, Ph.D.
Dr. Jasbir Seehra, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
302.22K
+19.52%
Mr. Julius Knowles
Mr. Julius Knowles
Independent Director
Independent Director
6.44K
+440.81%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Lead Independent Director
Lead Independent Director
5.45K
+2625.00%
Dr. Carl L. Gordon, Ph.D.
Dr. Carl L. Gordon, Ph.D.
Independent Director
Independent Director
5.25K
--
Mr. Nima Farzan
Mr. Nima Farzan
Independent Director
Independent Director
5.25K
--
Mr. Tomer Kariv, J.D.
Mr. Tomer Kariv, J.D.
Independent Director
Independent Director
5.25K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月27日 週日
更新時間: 7月27日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
持股股東
持股股東
佔比
Adar1 Capital Management LLC
13.27%
Pontifax Venture Capital
11.79%
Madison Avenue Partners LP
6.44%
J.P. Morgan Securities LLC
6.32%
The Vanguard Group, Inc.
6.32%
Other
55.86%
股東類型
持股股東
佔比
Hedge Fund
38.34%
Investment Advisor
21.28%
Investment Advisor/Hedge Fund
18.66%
Venture Capital
17.81%
Research Firm
10.83%
Private Equity
2.51%
Corporation
1.41%
Individual Investor
0.93%
Sovereign Wealth Fund
0.16%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
390
45.97M
113.19%
-7.37M
2025Q1
394
39.41M
98.81%
-8.43M
2024Q4
366
43.10M
106.25%
-873.01K
2024Q3
351
43.05M
114.83%
+404.61K
2024Q2
337
39.69M
109.09%
-4.15M
2024Q1
332
39.81M
110.03%
+1.08M
2023Q4
310
34.40M
109.87%
-229.62K
2023Q3
303
31.04M
104.70%
-2.97M
2023Q2
305
30.88M
104.58%
-2.59M
2023Q1
303
30.13M
102.36%
-2.18M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Adar1 Capital Management LLC
5.39M
13.27%
--
--
May 12, 2025
Pontifax Venture Capital
4.79M
11.79%
--
--
Apr 17, 2025
Madison Avenue Partners LP
2.61M
6.44%
+2.61M
--
May 14, 2025
J.P. Morgan Securities LLC
2.57M
6.32%
+2.38M
+1301.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.57M
6.32%
+616.06K
+31.59%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.51M
6.18%
+40.82K
+1.65%
Mar 31, 2025
Logos Global Management LP
2.00M
4.92%
+2.00M
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.51M
3.71%
+591.74K
+64.67%
Mar 31, 2025
State Street Global Advisors (US)
1.30M
3.21%
+99.16K
+8.24%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.26M
3.11%
+1.25M
+10339.95%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Janus Henderson Small Cap Growth Alpha ETF
1.06%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.79%
Federated Hermes MDT Small Cap Core ETF
0.45%
ALPS Medical Breakthroughs ETF
0.37%
SPDR S&P Biotech ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
iShares Biotechnology ETF
0.05%
查看更多
Janus Henderson Small Cap Growth Alpha ETF
佔比1.06%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.88%
Janus Henderson Small/Mid Cap Growth Alpha ETF
佔比0.79%
Federated Hermes MDT Small Cap Core ETF
佔比0.45%
ALPS Medical Breakthroughs ETF
佔比0.37%
SPDR S&P Biotech ETF
佔比0.18%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
iShares Biotechnology ETF
佔比0.05%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
